<DOC>
	<DOCNO>NCT00000970</DOCNO>
	<brief_summary>To examine safety tolerance administration ganciclovir foscarnet give together alternately ; determine interactive pharmacokinetics ( blood level ) profile long-term combined alternate therapy two drug . Additional objectives examine effect treatment control time cytomegalovirus ( CMV ) retinitis progression examine antiviral activity combine alternate ganciclovir/foscarnet treatment development antiviral resistance . Sight-threatening CMV retinitis occur least 6 percent AIDS patient . By 1991 ( US ) , may 6000 10000 patient CMV retinitis . Many clinical report suggest ganciclovir ( DHPG ) foscarnet antiviral effect CMV often associate clinical stabilization . Effectiveness ganciclovir foscarnet correlate weekly maintenance since toxicity dose-limiting 20 percent patient receive either drug long period , may beneficial long-term maintenance treatment combine alternate two drug low total weekly dose drug . This strategy may result great net antiviral effect less toxicity see either drug alone , toxicity drug quite different .</brief_summary>
	<brief_title>A Study Foscarnet Plus Ganciclovir Treatment Cytomegalovirus Eye Patients With AIDS Who Have Already Been Treated With Ganciclovir</brief_title>
	<detailed_description>Sight-threatening CMV retinitis occur least 6 percent AIDS patient . By 1991 ( US ) , may 6000 10000 patient CMV retinitis . Many clinical report suggest ganciclovir ( DHPG ) foscarnet antiviral effect CMV often associate clinical stabilization . Effectiveness ganciclovir foscarnet correlate weekly maintenance since toxicity dose-limiting 20 percent patient receive either drug long period , may beneficial long-term maintenance treatment combine alternate two drug low total weekly dose drug . This strategy may result great net antiviral effect less toxicity see either drug alone , toxicity drug quite different . All patient newly diagnose CMV retinitis complete 14-day course intravenous ganciclovir foscarnet induction therapy within 1 week prior study entry . The maintenance period consist 12-week study period follow 40 week follow-up period . Treatment consist either combine sequential daily maintenance therapy foscarnet ganciclovir alternate daily treatment ganciclovir one day foscarnet follow day .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemotherapy Kaposi 's sarcoma ( exclude interferon ) patient hematologically stable least 30 day prior entry . Zidovudine ( AZT ) , dideoxyinosine ( ddI ) , dideoxycytidine ( ddC ) first two week study period absolute neutrophil count &gt; 1000 cells/mm3 hemoglobin = &gt; 8 g/dl . Vancomycin . Fluconazole investigational triazoles ( e.g. , itraconazole , SCH 39304 ) disseminate fungal infection . Pneumocystis carinii pneumonia prophylaxis ( except parenteral pentamidine ) . Acyclovir appropriate medication may institute event appearance Herpes simplex virus ( HSV ) Varicella zoster virus ( VZV ) infection . GCSF GMCSF grade 4 neutropenia . Concurrent Treatment : Allowed : Recombinant human erythropoietin . Prior Medication : Required : Completion 14day course intravenous ganciclovir induction therapy ( 2.5 mg/kg IV q8h 5 mg/kg q12h 14 day ) foscarnet induction therapy ( 60 mg/kg q8h adjust renal function 14 day ) within 1 week prior study entry . Patients initiate study immediately upon complete ganciclovir induction therapy receive maintenance ganciclovir regimen 5 mg/kg/day 6 mg/kg/day 5 x week foscarnet regimen 90120 mg/kg/day initiate study drug . Patients must : Have diagnosis cytomegalovirus retinitis HIV infection . Be capable give informed consent . Patients &lt; 18 year age may participate consent parent , guardian , person power attorney . Allowed : History seizure disorder central nervous system ( CNS ) mass lesion . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Evidence tuberculous , diabetic hypertensive retinopathy . Osteomalacia , neoplasm metastatic bone bone disease . Any clinically significant pulmonary neurologic impairment ( example , patient intubate comatose ) . Retinal detachment . Corneal , lens , vitreous opacification preclude funduscopic exam . Concurrent Medication : Excluded : Immunomodulators , biologic response modifier investigational agent specifically allow . Aminoglycosides , amphotericin B , probenecid , parenteral pentamidine . Zidovudine ( AZT ) , dideoxyinosine ( ddI ) , dideoxycytidine ( ddC ) completion second week maintenance therapy . ddC use discourage prohibited paucity experience drug ganciclovir foscarnet . Anticytomegalovirus ( CMV ) therapy : Ganciclovir , CMV hyperimmune serum/globulin , interferon , immunomodulators . Prophylactic antiviral therapy acyclovir . Patients follow exclude : Active AIDSdefining opportunistic infection require therapy currently cause nephrotoxicity myelosuppression . Known hypersensitivity either study therapy . Prior Medication : Excluded : Foscarnet ganciclovir CMV retinitis ( exclude 14day induction period ) . Prior Treatment : Excluded : Cytomegalovirus ( CMV ) hyperimmune globulin within 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>